ArticleFrontiers in medicine2022
An Increased Aspartate to Alanine Aminotransferase Ratio Is Associated With a Higher Risk of Cognitive Impairment.
Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 32 citations in OpenAlex.
- Machine learning and data-driven inverse modeling of metabolomics unveil key processes of active aging.NPJ systems biology and applications · 2025Trial
- Estimated glucose disposal rate and markers of liver injury: A population-based study.Medicine · 2026Article
- ASL/ALT Ratio in Familial and Sporadic Parkinson's Disease: Insights From Cross-Sectional Logistic Analysis.Brain and behavior · 2026Article
- Investigating the protective and therapeutic potential of new generation antioxidant combinations in the brain: an experimental aging model.Biogerontology · 2026Article
- Predictive factors for mortality in acute mesenteric ischemia.Frontiers in surgery · 2026Article
- Anxiety and Depression Among Hepatitis B Inpatients in Shenzhen, China: A Cross-Sectional Study.Alpha psychiatry · 2025Article
- Association between liver biomarkers and risk of cognitive impairment and dementia: A systematic review and meta-analysis.Pakistan journal of medical sciences · 2025Review
- Bridging systemic metabolic dysfunction and Alzheimer's disease: the liver interface.Molecular neurodegeneration · 2025Review
- A Cross-Sectional Comparative Study: Could Asprosin and Peptide Tyrosine-Tyrosine Be Used in Schizophrenia to Define the Disease and Determine Its Phases?Diagnostics (Basel, Switzerland) · 2025Article
- Sleep quality, mental health, and cognitive function among older adults in Chinese communities: a cross-sectional study.Frontiers in public health · 2025Article
- Association of high serum aspartate transaminase to high density lipoprotein-cholesterol ratio with probable dementia among people living with HIV on antiretroviral therapy in Southwestern Uganda.SAGE open medicine · 2025Article
- Evaluation of Sarcopenia screening indices as predictors of mortality in older patients with Alzheimer's disease.BMC geriatrics · 2024Observational
- ApoE Gene Polymorphism and Clinical, Biochemical, and Sociodemographic Characteristics of Alzheimer's Disease Patients From Northern and Southern Regions of Kazakhstan.International journal of geriatric psychiatry · 2024Article
- Cognitive impairment in patients awaiting kidney and liver transplantation-A clinically relevant problem?Brain and behavior · 2024Article
- Non-linear association of liver enzymes with cognitive performance in the elderly: A cross-sectional study.PloS one · 2024Article
- Evaluation of Vicarious Somatosensory Experience in Diabetes Mellitus: Bases for Empathy and Social Cognition.Risk management and healthcare policy · 2024Article
- Correlation between theFrontiers in public health · 2024Article
- Association of liver function markers and apolipoprotein E ε4 with pathogenesis and cognitive decline in Alzheimer's disease.Frontiers in aging neuroscience · 2024Article
- Article
- The Role of Steroidomics in the Diagnosis of Alzheimer's Disease and Type 2 Diabetes Mellitus.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recent Alzheimer's disease (AD) hypotheses implicate that hepatic metabolic disorders might contribute to the disease pathogenesis of AD, but the mechanism remains unclear. Aims: To investigate whether the elevated aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ratio is associated with future cognitive decline, and to explore the possible mechanisms of liver enzymes affecting cognitive function. Methods: Three different clinical cohorts were included in the current study, including one cross-sectional study (Cohort 1) and two longitudinal follow-up studies (Cohort 2 and 3). All participants completed a detailed clinical evaluation, neuropsychological tests, and liver enzyme tests. In addition, some of them also underwent structural magnetic resonance imaging (MRI) scans. Results: Cohort 1 was derived from the CRC2017ZD02 program, including 135 amnestic mild cognitive impairment (aMCI) patients, 22 AD patients, and 319 normal controls. In this cross-sectional study, we found that the AST/ALT ratio was associated with AD ( Conclusion: An increased ratio of AST to ALT is associated with a higher risk of cognitive impairment and may impair cognitive function by affecting hippocampal volume.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.